Skip to main content

Table 1 Baseline characteristics of the subjects (n = 684)

From: Predictors of decline in walking ability in community-dwelling Alzheimer’s disease patients: Results from the 4-years prospective REAL.FR study

Variables

Values

Age (mean, SD, years)

77.84 (6.82)

Gender, female (%)

71.20

Level of education (% > primary school)

78.79

Age at diagnosis (mean, SD, years)

76.77 (7.00)

Cardiovascular risk factorsa (%)

59.65

Cardiovascular disease (%)

25.59

Painful osteoarthritis (%)

8.50

Depression (%)

37.17

Comorbidity (%)

 

 0

28.09

 1

37.96

  ≥ 2

33.95

MNA (% ≤ 23.5)

33.03

Zarit score (mean, SD)

22.63 (15.87)

MMSE (mean, SD)

20.02 (4.23)

MMSE (%)

 

  > 20

50.44

 16 to 20

32.55

  < 15

17.01

One leg balance test (% abnormal)

15.06

ADL score (mean, SD)

5.45 (0.87)

Weight (kg, mean, SD)

62.63 (12.76)

BMI (%)

 

  < 20

13.33

 20 to 25

43.26

 25 to 30

33.63

  ≥ 30

9.78

NPI (mean, SD)

15.35 (15.30)

NPI (%)

 

 Delusions

16.23

 Hallucination

6.73

 Agitation/aggression

36.99

 Depression

38.74

 Anxiety

42.25

 Elation/euphoria

7.02

 Apathy

53.51

 Disinhibition

10.96

 Irritability/lability

36.26

 Aberrant motor behavior

21.78

 Sleep disorder

14.62

 Appetite disorder

22.11

Treatment (%)

 

 AChE inhibitors

89.33

 Psychotropic treatments

50.15

 Anti-Parkinsonian treatment

1.32

Computed tomography scan (%)

 

 Normal

22.58

 Atrophy alone

26.69

 Lacuna or stroke

9.68

 Hypodensity of the white matter

12.17

 Other

8.65

 CT scan not performed

20.23

  1. aCardiovascular risk factors, diabetes mellitus, past or current smoking, hypertension, dyslipidemia, cardiovascular disease, atrial fibrillation, angina, heart failure, myocardial infarction, peripheral vascular disease; comorbidity, respiratory, sensorial, gastro-intestinal, kidney, urinary, neurological disease, endocrine, alcohol and other; anti-parkinsonian treatment, dopamine agonist or dopaminergic agent; psychotropic treatments, anxiolytics, neuroleptics, serotonin reuptake inhibitor and other antidepressants; AChE inhibitors, acetylcholinesterase (AChE) inhibitors (galantamine, donepezil or rivastigmine); ADL, Activities of Daily Living scale; BMI, body mass index; MNA, Mini-Nutritional Assessment, ≤23.5 versus >23.5; MMSE, Mini-Mental State Examination; NPI, Neuro-Psychiatric Inventory.